Full View

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

H Huynh, VC Ngo, HN Koong, D Poon… - Journal of cellular …, 2009 - Wiley Online Library
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …
被引用次数：150 相关文章

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

H Huynh, HN Koong, D Poon… - Journal of cellular …, 2009 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen-activated …

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

H Huynh, HN Koong, D Poon, SP Choo… - Journal of Cellular …, 2009 - search.proquest.com
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.

H Huynh, VC Ngo, HN Koong, D Poon… - Journal of Cellular …, 2009 - europepmc.org
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.

H Huynh, VC Ngo, HN Koong, D Poon… - Journal of Cellular …, 2009 - search.ebscohost.com
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen-activated …

[引用][C] Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

H Huynh, HNK Van Chanh Ngo, D Poon… - Journal of Cellular and …, 2009 - cir.nii.ac.jp
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular
carcinoma | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
[HTML] nih.gov

[HTML][HTML] Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

H Huynh, HN Koong, D Poon, SP Choo… - Journal of Cellular …, 2009 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …
[PDF] academia.edu

[PDF][PDF] Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

CH Thng, P Chow, HS Ong, A Chung, KC Soo - J. Cell. Mol. Med, 2009 - academia.edu
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen-activated …

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.

H Huynh, VC Ngo, HN Koong, D Poon… - Journal of Cellular …, 2009 - europepmc.org
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …
[PDF] academia.edu

[PDF][PDF] Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

CH Thng, P Chow, HS Ong, A Chung, KC Soo - J. Cell. Mol. Med, 2009 - academia.edu
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen-activated …